BeamWorks

About BeamWorks

BeamWorks is a medical artificial intelligence research company established in 2021 by co-founders and co-CEOs Kim Won-hwa and Kim Jae-il, experts in imaging medicine and computer engineering respectively. The company focuses on developing AI solutions to facilitate expert-level cancer diagnosis globally and provide reliable medical consultations.

The firm's flagship product line is the CadAI-Series, which includes AI-powered software for cancer diagnosis. In July 2024, its CadAI-B for Breast solution received approval from South Korea's Ministry of Food and Drug Safety. This software assists in detecting and diagnosing breast cancer by analyzing ultrasound images in real-time, with an AI inference speed of under 0.02 seconds. CadAI-B aims to improve the accuracy of ultrasound readings and reduce unnecessary biopsies. The technology was trained on over 600,000 breast ultrasound cases to enhance its accuracy, particularly for dense breasts which are common in more than 50% of Asian women. It demonstrates a detection sensitivity of 96% and a differential diagnosis performance of 95%. The software operates on-device, even on mobile PCs, allowing it to function in real-time with ultrasound equipment without needing a server. The series also includes CadAI-T for thyroid cancer diagnosis and CadAI-M for mammography. Following the success of CadAI-B, the company plans to launch CadAI-T.

BeamWorks has also developed the Emergency-Series, conversational AI applications for emergency situations. Emergency Smart is designed for the general public for triage, while Emergency Pro is for emergency medical personnel. Additionally, the Alexandria-Series includes an online training platform for AI ultrasound diagnosis (Alexandria-Edu) and a multi-center international telemedicine solution (Alexandria-Link). The company has established partnerships with major global corporations like GE Healthcare and Siemens Healthineus as it expands into overseas markets.